Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Depreciation & Amortization (CF) (2016 - 2025)

Iovance Biotherapeutics has reported Depreciation & Amortization (CF) over the past 12 years, most recently at $3.7 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $3.7 million for Q4 2025, up 13.71% from a year ago — trailing twelve months through Dec 2025 was $12.9 million (up 4.78% YoY), and the annual figure for FY2025 was $12.9 million, up 14.28%.
  • Depreciation & Amortization (CF) for Q4 2025 was $3.7 million at Iovance Biotherapeutics, up from $2.9 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for IOVA hit a ceiling of $3.7 million in Q4 2025 and a floor of $2.8 million in Q1 2023.
  • Median Depreciation & Amortization (CF) over the past 3 years was $3.0 million (2023), compared with a mean of $3.1 million.
  • Peak annual rise in Depreciation & Amortization (CF) hit 13.71% in 2025, while the deepest fall reached 6.67% in 2025.
  • Iovance Biotherapeutics' Depreciation & Amortization (CF) stood at $2.9 million in 2023, then increased by 11.05% to $3.3 million in 2024, then increased by 13.71% to $3.7 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $3.7 million (Q4 2025), $2.9 million (Q3 2025), and $3.4 million (Q2 2025) per Business Quant data.